• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR plus BC)

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    AnnOncolHowell.pdf
    Size:
    127.2Kb
    Format:
    PDF
    Description:
    From Unpaywall
    Download
    Authors
    Howell, Sacha J
    Krebs, Matthew G
    Lord, S.
    Kenny, L.
    Bahl, A.
    Clack, G.
    Ainscow, E.
    Arkenau, H. T.
    Mansi, J. L.
    Palmieri, C.
    Richards, P.
    Jeselsohn, R.
    Mitri, Z.
    Gradishar, W. J.
    Sardesai, S.
    O'Shaughnessy, J.
    Lehnert, M.
    Ali, S.
    McIntosh, S.
    Coombes, R. C.
    Show allShow less
    Affiliation
    Division Of Cancer Sciences, The University of Manchester, Manchester, UK
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background CDK7 inhibition is a promising therapeutic strategy in cancer; acting as a regulator of transcription, the cell cycle and endocrine receptor signalling. Patients with HR+BC post CDK4/6 inhibitor treatment have a poor prognosis; median progression free survival (mPFS) of ? 8 weeks for fulvestrant post CDK4/6i in HR+BC [1,2]. Pre-clinical HR+BC models indicate the potential for synergy when the CDK7 inhibitor samuraciclib is combined with fulvestrant [3]. Methods This single arm cohort assessed the tolerability and efficacy of samuraciclib in combination with fulvestrant in patients with advanced HR+BC; all patients had previously received an aromatase inhibitor and a CDK4/6 inhibitor for advanced disease. Results 31 patients with HR+BC received the combination of standard dose with fulvestrant and samuraciclib. 6 patients received samuraciclib dose of 240mg once daily (OD) and 25 patients a dose of 360mg (OD). The combination treatment was generally well tolerated, with adverse drug reactions (AE) of note being G1-2 nausea, vomiting and diarrhoea; the majority of patients staying on treatment until disease progression. RECIST evaluation indicates evidence of reduction in tumor disease burden, including a partial response in one patient who has been on treatment for ? 1 year. Graphic illustrations of data, including �waterfall� and �swimmer� plots, will be presented. Conclusions Samuraciclib has demonstrated an acceptable safety profile with evidence of anti-tumour activity in combination with fulvestrant for patients with advanced HR+BC who have progressed on their prior CDK4/6i.
    Citation
    Howell SJ, Krebs MG, Lord S, Kenny L, Bahl A, Clack G, et al. 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC). Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S477�8.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624663
    DOI
    10.1016/j.annonc.2021.08.548
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.08.548
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.08.548
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.